by Juliette Boynton | Jan 1, 2020 | Briefings, UK
The Supreme Court issued its judgement recently in relation to the application for employee compensation by Professor Shanks considering use of the “outstanding benefit” test in relation to a large company. Prof Shanks was employed by CRL, a wholly owned...
by David Eyre | Oct 1, 2019 | Briefings, UK, UPC, US & International
Currently, the cost of validating a European patent in multiple European jurisdictions can be prohibitive and a prudent Patentee may have to select a subset of EPO countries to protect their invention in. In contrast, the unitary patent offers the advantages of wider...
by Sean Hughes | Oct 1, 2019 | Briefings, US & International
Background US patents have a term of 20 years from the filing date of the patent application. A long period of prosecution, however, can effectively diminish the patent term, since a patent is only enforceable after grant. In an effort to make things fairer, the USPTO...
by David Eyre | Sep 1, 2019 | Briefings, US & International
Eli Lilly is the patent holder of a drug called pemetrexed (Lilly brand “Alimta”) that has been the subject of court proceedings in the UK, which we have reported previously. This case concerns a related issue during US proceedings in which the US Federal...
by Sean Hughes | Aug 1, 2019 | UK
Background In Illumina v TDL & Ariosa [2019] EWHC 1159, an interesting question at hand was whether Illumina had to get the Court’s permission to rely on expert evidence which was used in a different case and then served under a hearsay notice in the present...
Recent Comments